Methods and compositions for modulating a genome

US12031129B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-12031129-B2
Application numberUS-201916706448-A
CountryUS
Kind codeB2
Filing dateDec 6, 2019
Priority dateAug 28, 2018
Publication dateJul 9, 2024
Grant dateJul 9, 2024

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Methods and compositions for modulating a target genome are disclosed. The composition may comprise a first RNA encoding a polypeptide comprising a retrotransposase reverse transcriptase domain and a retrotransposase endonuclease domain. The composition may also comprise a second RNA comprising a sequence that binds the polypeptide and a heterologous object sequence. The composition may insert the sequence of the heterologous object sequence into a target DNA.

First claim

Opening claim text (preview).

What is claimed is: 1. A composition for modifying DNA, the composition comprising a first engineered RNA and a second engineered RNA, wherein: (a) the first engineered RNA encodes a polypeptide, wherein the polypeptide comprises (i) a reverse transcriptase domain and (ii) a endonuclease domain, wherein the polypeptide comprises an amino acid sequence according to any of SEQ ID NOs: 1016-1021; and (b) the second engineered RNA comprises a template RNA, wherein the template RNA comprises (i) a sequence according to SEQ ID NO: 1140 that binds the encoded polypeptide and (ii) a heterologous object sequence, wherein (a) and (b) are separate RNAs. 2. The composition of claim 1 , wherein the template RNA further comprises a sequence comprising at least 20 nucleotides of at least 80% identity to a target DNA. 3. The composition of claim 2 , wherein the target DNA is a genomic safe harbor (GSH) site. 4. The composition of claim 1 , wherein the template RNA comprises: (iii) at least 10 bases of identity to a target DNA at the 3′ end of the template RNA, and (iv) at least 10 bases of identity to the target DNA at the 5′ end of the template RNA. 5. The composition of claim 1 , wherein the template RNA comprises: (iii) at least 3 bases of identity to a target DNA at the 3′ end of the template RNA, and (iv) at least 3 bases of identity to the target DNA at the 5′ end of the template RNA. 6. The composition of claim 1 , wherein the sequence that binds the polypeptide comprises one or both of a 3′ untranslated region and a 5′ untranslated region. 7. The composition of claim 1 , wherein the heterologous object sequence encodes an enzyme, a membrane protein, a blood factor, an intracellular protein, an extracellular protein, a structural protein, a signaling protein, a regulatory protein, a transport protein, or a motor protein. 8. The composition of claim 1 , wherein the heterologous object sequence comprises a non-coding sequence or a regulatory sequence. 9. The composition of claim 1 , wherein the heterologous object sequence encodes a therapeutic polypeptide or fragment thereof. 10. The pharmaceutical composition of claim 8 , wherein the regulatory sequence is a promoter. 11. The composition of claim 1 , wherein the polypeptide further comprises one or both of a nuclear localization signal and a nucleolar localization signal. 12. The composition of claim 1 , which comprises only RNA, or comprises more RNA than DNA by an RNA:DNA ratio of at least 10:1, 20:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, or 100:1. 13. The composition of claim 1 , which comprises no more than 1%, 0.5%, 0.2%, 0.1%, 0.05%, 0.02%, or 0.01% DNA by mass or by molar amount of nucleic acid. 14. The composition of claim 1 , which is capable of modifying DNA in the absence of homologous recombination activity. 15. The composition of claim 1 , wherein the template RNA does not encode a reverse transcriptase. 16. The composition of claim 1 , wherein the template RNA does not encode an endonuclease.

Assignees

Inventors

Classifications

  • Nucleic acids vectors · CPC title

  • in mammalian cells · CPC title

  • for animal cells · CPC title

  • Ribonucleases {[RNase]; Deoxyribonucleases [DNase]} · CPC title

  • involving clustered regularly interspaced short palindromic repeats [CRISPR] · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US12031129B2 cover?
Methods and compositions for modulating a target genome are disclosed. The composition may comprise a first RNA encoding a polypeptide comprising a retrotransposase reverse transcriptase domain and a retrotransposase endonuclease domain. The composition may also comprise a second RNA comprising a sequence that binds the polypeptide and a heterologous object sequence. The composition may insert …
Who is the assignee on this patent?
Flagship Pioneering Innovations Vi Llc
What technology area does this patent fall under?
Primary CPC classification C12N15/102. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).